TCRX Stock Price, TScan Therapeutics, Inc. Quote, Chart

Market Summary

USD8.97+0.07

Delayed

0.79%

TCRX Stock Price

View Fullscreen

TCRX RSI Chart

TCRX Valuation

Market Cap

851.0M

Price/Earnings (Trailing)

-8.8

Price/Sales (Trailing)

40.43

Price/Free Cashflow

-12.15

TCRX Price/Sales (Trailing)

TCRX Profitability

Return on Equity

-78.68%

Return on Assets

-40.18%

Free Cashflow Yield

-8.23%

TCRX Fundamentals

TCRX Revenue

Rev. Growth (Yr)

132.99%

Rev. Growth (Qtr)

85.52%

TCRX Earnings

Earnings (TTM)

-96.8M

Earnings Growth (Yr)

-33.4%

Earnings Growth (Qtr)

-53.47%

Breaking Down TCRX Revenue

Last 7 days

16.0%

Last 30 days

32.9%

Last 90 days

32.3%

Trailing 12 Months

173.5%

How does TCRX drawdown profile look like?

TCRX Financial Health

Current Ratio

5.23

Debt/Equity

0.19

Debt/Cashflow

-2.86

TCRX Investor Care

Shares Dilution (1Y)

291.63%

Diluted EPS (TTM)

-0.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	17.3M	16.4M	16.9M	21.0M
2022	11.1M	12.3M	13.3M	13.5M
2021	3.3M	5.6M	7.9M	10.1M
2020	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of TScan Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 19, 2023	barberich timothy j	bought	1,575	4.9685	317	-
Dec 18, 2023	barberich timothy j	bought	140,881	4.8866	28,830	-
Dec 14, 2023	klencke barbara	bought	25,400	5.08	5,000	-
Jun 02, 2023	barberich timothy j	bought	99,563	2.6284	37,880	-
May 31, 2023	lynx1 capital management lp	sold	-38,804	2.51977	-15,400	-
May 31, 2023	lynx1 capital management lp	sold	-25,148	2.5148	-10,000	-
Dec 28, 2022	silver brian m.	bought	4,941	1.5646	3,158	chief financial officer
Dec 27, 2022	silver brian m.	bought	4,276	1.5047	2,842	chief financial officer
May 18, 2022	southwell david p	bought	89,821	3.59284	25,000	chief executive officer
May 11, 2022	baker bros. advisors lp	bought	51,349	1.9853	25,865	-

Which funds bought or sold TCRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	83.13	728,360	1,215,880	-%
May 15, 2024	Lynx1 Capital Management LP	unchanged	-	11,023,900	41,483,300	10.75%
May 15, 2024	BVF INC/IL	unchanged	-	6,307,790	23,736,400	0.65%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	759	1,889,010	2,065,580	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	90,770	90,770	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-28.31	-12,187	502,602	0.01%
May 15, 2024	Walleye Capital LLC	added	195	313,035	416,675	-%
May 15, 2024	STATE STREET CORP	added	120	715,687	1,071,900	-%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	new	-	156,704	156,704	0.04%
May 15, 2024	Man Group plc	added	53.42	320,182	614,072	-%

Are Funds Buying or Selling TCRX?

Are funds buying TCRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TCRX

No. of Funds

Unveiling TScan Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 29, 2024	cormorant asset management, lp	5.15%	2,500,000	SC 13G
Apr 23, 2024	baker bros. advisors lp	6.1%	2,828,938	SC 13D/A
Feb 14, 2024	k2 healthventures equity trust llc	985%	4,588,034	SC 13G/A
Feb 09, 2024	gv 2017, l.p.	1.5%	641,848	SC 13G/A
Feb 08, 2024	pitango healthtech fund i, l.p.	4.2%	2,022,034	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	8.96%	3,900,000	SC 13G/A
Jun 12, 2023	adage capital partners gp, l.l.c.	9.35%	4e+06	SC 13G
Jun 08, 2023	blackrock inc.	3.0%	1,267,188	SC 13G/A
Jun 05, 2023	biotechnology value fund l p	6.8%	3,023,416	SC 13G
Jun 05, 2023	ecor1 capital, llc	11.7%	5e+06	SC 13G

Recent SEC filings of TScan Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 02, 2024	3	Insider Trading
Apr 30, 2024	ARS	ARS
Apr 30, 2024	DEF 14A	DEF 14A
Apr 30, 2024	DEFA14A	DEFA14A
Apr 29, 2024	SC 13G	Major Ownership Report
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading

Peers (Alternatives to TScan Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

TScan Therapeutics, Inc. News

Latest updates

TScan Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-100.0%	-	7,211	3,887	3,148	6,803	3,095	3,363	4,056	3,021	2,854	2,412	2,848	2,027	1,159	290
Operating Expenses	11.8%	31,939	28,568	28,635	27,758	29,546	21,744	19,941	19,302	19,184	17,056	18,254	13,527	9,945	-	7,461
S&GA Expenses	-100.0%	-	6,162	5,894	6,531	7,767	6,140	4,910	4,808	4,494	4,448	4,048	2,726	2,606	-	1,648
R&D Expenses	10.9%	24,857	22,406	22,741	21,227	21,779	15,604	15,031	14,494	14,690	12,608	14,206	10,801	7,339	-	5,813
Interest Expenses	12.6%	959	852	982	969	956	-	201	-	-	-	-	-	-	-	-
Net Income	-53.5%	-30,100	-19,613	-22,997	-24,045	-22,563	-18,723	-16,245	-15,097	-16,156	-14,200	-15,839	-10,674	-7,912	-	-7,170
Net Income Margin	-8.4%	-4.60*	-4.24*	-5.22*	-4.97*	-4.19*	-4.89*	-4.64*	-4.97*	-5.11*	-4.79*	-3.32*	-4.65*	-7.80*	-24.08*	-
Free Cashflow	-23.7%	-29,972	-24,235	6,598	-22,442	-24,425	-17,387	-17,426	-15,260	-20,655	-16,591	-14,493	-14,618	-12,916	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-11.5%	241	272	291	317	174	199	165	152	168	188	205	130	50.00
Current Assets	-15.2%	165	194	218	242	101	124	141	129	146	166	187	110	36.00
Cash Equivalents	9.1%	146	133	155	209	96.00	120	137	126	141	166	182	106	35.00
Net PPE	-7.0%	7.00	8.00	9.00	8.00	9.00	10.00	10.00	11.00	11.00	12.00	11.00	10.00	6.00
Liabilities	-2.8%	118	121	122	126	96.00	100	49.00	21.00	23.00	27.00	31.00	31.00	33.00
Current Liabilities	5.6%	31.00	30.00	33.00	35.00	14.00	17.00	17.00	17.00	18.00	21.00	23.00	21.00	17.00
Long Term Debt	-12.2%	23.00	27.00	29.00	30.00	30.00	29.00	29.00	-	-	-	-	-	-
LT Debt, Current	103.1%	7.00	3.00	1.00	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	27.00	29.00	30.00	30.00	29.00	29.00	-	-	-	-	-	-
Shareholder's Equity	-18.5%	123	151	169	191	78.00	99.00	117	132	146	161	174	-	-
Retained Earnings	-12.2%	-277	-247	-228	-205	-180	-158	-139	-123	-108	-92.16	-77.96	-62.12	-43.53
Additional Paid-In Capital	0.6%	401	398	397	396	259	258	256	255	254	253	252	2.00	1.00
Shares Outstanding	44.6%	95.00	66.00	56.00	47.00	24.00	24.00	24.00	24.00	24.00	12.00	8.00	1.00	1.00
Float	-	-	-	-	74.00	-	-	-	49,197	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-23.1%	-29,267	-23,766	8,017	-22,022	-23,587	-16,010	-17,002	-13,367	-20,124	-14,380	-13,640	-10,700	-9,957	-	-	-
Share Based Compensation	32.3%	1,984	1,500	1,341	1,220	1,147	1,297	1,246	1,024	984	784	885	503	344	-	-	-
Cashflow From Investing	1790.4%	36,163	1,913	-61,414	-420	-838	-1,377	-424	-1,893	-531	-2,211	-853	-3,918	-2,959	-	-	-
Cashflow From Financing	1257.9%	258	19.00	-252	-	-	108	29,129	31.00	88.00	120	90,608	-686	99,626	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TCRX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Collaboration and license revenue	$ 566	$ 6,803
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Collaboration and license revenue	Collaboration and license revenue
Operating expenses:
Research and development	$ 24,857	$ 21,779
General and administrative	7,082	7,767
Total operating expenses	31,939	29,546
Loss from operations	(31,373)	(22,743)
Other (expense) income:
Interest and other income, net	2,190	1,136
Interest expense	(959)	(956)
Total other income	1,231	180
Net loss	$ (30,142)	$ (22,563)
Net loss per share, basic	$ (0.32)	$ (0.93)
Net loss per share, diluted	$ (0.32)	$ (0.93)
Weighted average common shares outstanding- basic	94,875,893	24,225,954
Weighted average common shares outstanding-diluted	94,875,893	24,225,954

TCRX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 140,513	$ 133,359
Marketable securities	22,270	58,685
Prepaid expenses and other current assets	1,938	2,193
Total current assets	164,721	194,237
Property and equipment, net	7,201	7,742
Right-of-use assets	62,232	63,492
Restricted cash	5,031	5,031
Long-term deposit and other assets	1,647	1,647
Total assets	240,832	272,149
Current liabilities:
Accounts payable	2,123	2,374
Accrued expenses and other current liabilities	8,786	10,716
Operating lease liability, current portion	3,338	3,246
Deferred revenue, current portion	10,435	10,137
Current portion of long-term debt	6,797	3,347
Total current liabilities	31,479	29,820
Deferred revenue, net of current portion	4,758	5,622
Operating lease liability, net of current portion	58,179	59,140
Long-term debt and accrued interest	23,449	26,700
Total liabilities	117,865	121,282
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Additional paid-in capital	400,701	398,459
Accumulated deficit	(277,739)	(247,597)
Total stockholders' equity	122,967	150,867
Total liabilities and stockholders' equity	240,832	272,149
Voting Common Stock
Stockholders' equity:
Common stock	4	4
Non-voting Common Stock
Stockholders' equity:
Common stock	$ 1	$ 1

About TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

CEO	Dr. Gavin MacBeath Ph.D.
WEBSITE	tscan.com
INDUSTRY	Biotechnology
EMPLOYEES	135

TScan Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for TScan Therapeutics, Inc.? What does TCRX stand for in stocks?

TCRX is the stock ticker symbol of TScan Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TScan Therapeutics, Inc. (TCRX)?

As of Fri May 17 2024, market cap of TScan Therapeutics, Inc. is 851.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TCRX stock?

You can check TCRX's fair value in chart for subscribers.

What is the fair value of TCRX stock?

You can check TCRX's fair value in chart for subscribers. The fair value of TScan Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TScan Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TCRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TScan Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TCRX is over valued or under valued. Whether TScan Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact TScan Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TCRX.

What is TScan Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TCRX's PE ratio (Price to Earnings) is -8.8 and Price to Sales (PS) ratio is 40.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TCRX PE ratio will change depending on the future growth rate expectations of investors.